Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 4
Submit an article Journal homepage
156
Views
0
CrossRef citations to date
0
Altmetric
Review

TGF-β, IL-6, IL-17 and CTGF direct multiple pathologies of chronic cardiac allograft rejection

Adam J Booth1 Division of Pulmonary & Critical Care, Department of Internal Medicine, University of Michigan Medical Center, 6240 MSRBIII/0624, 1150 W Medical Center Drive, Ann Arbor, MI48109, USACorrespondence[email protected]
View further author information
&
D Keith Bishop1 Division of Pulmonary & Critical Care, Department of Internal Medicine, University of Michigan Medical Center, 6240 MSRBIII/0624, 1150 W Medical Center Drive, Ann Arbor, MI48109, USAView further author information
Pages 511-520 | Published online: 16 Jul 2010

Bibliography

  • Lloyd-Jones D , AdamsRJ, BrownTMet al.: Heart disease and stroke statistics – 2010 update. A report from the American Heart Association.Circulation119(3) , 480–486 (2009).
  • Keck BM , BennettLE, RosendaleJ, DailyOP, NovickRJ, HosenpudJD: Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation.Clin. Transpl.35–49 (1999).
  • Waaga AM , GasserM, LaskowskiI, TilneyNL: Mechanisms of chronic rejection.Curr. Opin. Immunol.12(5) , 517–521 (2000).
  • Mehra MR : Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy.Am. J. Transplant.6(6) , 1248–1256 (2006).
  • Mannon RB : Therapeutic targets in the treatment of allograft fibrosis.Am. J. Transplant.6(5 Pt 1) , 867–875 (2006).
  • Valantine H : Cardiac allograft vasculopathy after heart transplantation: risk factors and management.J. Heart Lung Transplant.23(5 Suppl.) , S187–S193 (2004).
  • Weiss MJ , MadsenJC, RosengardBR, AllanJS: Mechanisms of chronic rejection in cardiothoracic transplantation.Front. Biosci.13 , 2980–2988 (2008).
  • Hornick P , RoseM: Chronic rejection in the heart.Methods Mol. Biol.333 , 131–144 (2006).
  • Bieber CP , StinsonEB, ShumwayNE, PayneR, KosekJ: Cardiac transplantation in man. VII. Cardiac allograft pathology.Circulation41(5) , 753–772 (1970).
  • Yeung AC , DavisSF, HauptmanPJet al.: Incidence and progression of transplant coronary artery disease over 1 year: results of a multicenter trial with use of intravascular ultrasound. Multicenter Intravascular Ultrasound Transplant Study Group.J. Heart Lung Transplant.14(6 Pt 2) , S215–S220 (1995).
  • Weis M , von Scheidt W: Cardiac allograft vasculopathy: a review. Circulation96(6) , 2069–2077 (1997).
  • Wahlers T , MuggeA, OppeltPet al.: Coronary vasculopathy following cardiac transplantation and cyclosporine immunosuppression: preventive treatment with angiopeptin, a somatostatin analog.Transplant. Proc.26(5) , 2741–2742 (1994).
  • Ewel CH , FoeghML: Chronic graft rejection: accelerated transplant arteriosclerosis.Immunol. Rev.134 , 21–31 (1993).
  • Li H , TanakaK, ChhabraA, OeserB, KobashigawaJA, TobisJM: Vascular remodeling 1 year after cardiac transplantation.J. Heart Lung Transplant.26(1) , 56–62 (2007).
  • Raichlin E , BaeJH, KhalpeyZet al.: Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation.Circulation116(23) , 2726–2733 (2007).
  • Eisen H : Long-term cardiovascular risk in transplantation – insights from the use of everolimus in heart transplantation.Nephrol. Dial. Transplant.21(Suppl. 3) , III9–III13 (2006).
  • Segovia J , Gomez-BuenoM, Alonso-PulponL: Treatment of allograft vasculopathy in heart transplantation.Expert Opin. Pharmacother.7(17) , 2369–2383 (2006).
  • Tullius SG , TilneyNL: Both alloantigen-dependent and -independent factors influence chronic allograft rejection.Transplantation59(3) , 313–318 (1995).
  • Torre-Amione G , WallaceCK, YoungJBet al.: The effect of etanercept on cardiac transplant recipients: a study of TNFa antagonism and cardiac allograft hypertrophy.Transplantation84(4) , 480–483 (2007).
  • Weber KT , SunY, TyagiSC, CleutjensJP: Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms.J. Mol. Cell. Cardiol.26(3) , 279–292 (1994).
  • Phan SH : Biology of fibroblasts and myofibroblasts.Proc. Am. Thorac. Soc.5(3) , 334–337 (2008).
  • Kovacs EJ , DiPietroLA: Fibrogenic cytokines and connective tissue production.FASEB J.8(11) , 854–861 (1994).
  • Wu GD , TuanTL, BowdishMEet al.: Evidence for recipient derived fibroblast recruitment and activation during the development of chronic cardiac allograft rejection.Transplantation76(3) , 609–614 (2003).
  • Wu GD , BowdishME, JinYSet al.: Contribution of mesenchymal progenitor cells to tissue repair in rat cardiac allografts undergoing chronic rejection.J. Heart Lung Transplant.24(12) , 2160–2169 (2005).
  • Wu GD , NoltaJA, JinYSet al.: Migration of mesenchymal stem cells to heart allografts during chronic rejection.Transplantation75(5) , 679–685 (2003).
  • Sartore S , ChiavegatoA, FagginEet al.: Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant.Circ. Res.89(12) , 1111–1121 (2001).
  • Zeisberg EM , TarnavskiO, ZeisbergMet al.: Endothelial-to-mesenchymal transition contributes to cardiac fibrosis.Nat. Med.13(8) , 952–961 (2007).
  • Goumans MJ , van Zonneveld AJ, ten Dijke P: Transforming growth factor β-induced endothelial-to-mesenchymal transition: a switch to cardiac fibrosis? Trends Cardiovasc. Med.18(8) , 293–298 (2008).
  • Mazzucchelli L : Protein S100A4: too long overlooked by pathologists?Am. J. Pathol.160(1) , 7–13 (2002).
  • Cook HT : The origin of renal fibroblasts and progression of kidney disease.Am. J. Pathol.176(1) , 22–24 (2010).
  • Humphreys BD , LinSL, KobayashiAet al.: Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis.Am. J. Pathol.176(1) , 85–97).
  • Suzuki J , IsobeM, AikawaMet al.: Nonmuscle and smooth muscle myosin heavy chain expression in rejected cardiac allografts. A study in rat and monkey models.Circulation94(5) , 1118–1124 (1996).
  • Ramirez AM , ShenZ, RitzenthalerJD, RomanJ: Myofibroblast transdifferentiation in obliterative bronchiolitis: TGF-β signaling through Smad3-dependent and -independent pathways.Am. J. Transplant.6(9) , 2080–2088 (2006).
  • Eyden B : The myofibroblast: phenotypic characterization as a prerequisite to understanding its functions in translational medicine.J. Cell. Mol. Med.12(1) , 22–37 (2008).
  • Subramanian SV , KelmRJ, PolikandriotisJA, OroszCG, StrauchAR: Reprogramming of vascular smooth muscle α-actin gene expression as an early indicator of dysfunctional remodeling following heart transplant.Cardiovasc. Res.54(3) , 539–548 (2002).
  • Subramanian SV , OroszCG, StrauchAR: Vascular smooth muscle α-actin expression as an indicator of parenchymal cell reprogramming in cardiac allografts.Transplantation65(12) , 1652–1656 (1998).
  • Serini G , Bochaton-PiallatML, RoprazPet al.: The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-β1.J. Cell Biol.142(3) , 873–881 (1998).
  • Muro AF , MorettiFA, MooreBBet al.: An essential role for fibronectin extra type III domain A in pulmonary fibrosis.Am. J. Respir. Crit. Care Med.177(6) , 638–645 (2008).
  • Madani S , De Girolamo S, Munoz DM, Li RK, Sweeney G: Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovasc. Res.69(3) , 716–725 (2006).
  • Parkes JG , LiuY, SirnaJB, TempletonDM: Changes in gene expression with iron loading and chelation in cardiac myocytes and non-myocytic fibroblasts.J. Mol. Cell. Cardiol.32(2) , 233–246 (2000).
  • Brown RD , AmblerSK, MitchellMD, LongCS: The cardiac fibroblast: therapeutic target in myocardial remodeling and failure.Annu. Rev. Pharmacol. Toxicol.45 , 657–687 (2005).
  • Camelliti P , BorgTK, KohlP: Structural and functional characterisation of cardiac fibroblasts.Cardiovasc. Res.65(1) , 40–51 (2005).
  • Eghbali M : Cardiac fibroblasts: function, regulation of gene expression, and phenotypic modulation.Basic Res. Cardiol.87(Suppl. 2) , 183–189 (1992).
  • Camelliti P , GreenCR, KohlP: Structural and functional coupling of cardiac myocytes and fibroblasts.Adv. Cardiol.42 , 132–149 (2006).
  • Weber KT , JanickiJS, ShroffSG, PickR, ChenRM, BasheyRI: Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium.Circ. Res.62(4) , 757–765 (1988).
  • Weber KT , JalilJE, JanickiJS, PickR: Myocardial collagen remodeling in pressure overload hypertrophy. A case for interstitial heart disease.Am. J. Hypertens.2(12 Pt 1) , 931–940 (1989).
  • Weber KT , BrillaCG: Factors associated with reactive and reparative fibrosis of the myocardium.Basic Res. Cardiol.87(Suppl. 1) , 291–301 (1992).
  • Silver MA , PickR, BrillaCG, JalilJE, JanickiJS, WeberKT: Reactive and reparative fibrillar collagen remodelling in the hypertrophied rat left ventricle: two experimental models of myocardial fibrosis.Cardiovasc. Res.24(9) , 741–747 (1990).
  • Weber KT , BrillaCG, JanickiJS: Myocardial fibrosis: functional significance and regulatory factors.Cardiovasc. Res.27(3) , 341–348 (1993).
  • Nicoletti A , MichelJB: Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors.Cardiovasc. Res.41(3) , 532–543 (1999).
  • Diaz JA , BoothAJ, LuG, WoodSC, PinskyDJ, BishopDK: Critical role for IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection.Am. J. Transplant.9(8) , 1773–1783 (2009).
  • Torre-Amione G : Cardiac allograft hypertrophy: a new target for therapy, a surrogate marker for surviva?.Am. J. Transplant.9(1) , 7–8 (2009).
  • Matsui Y , SadoshimaJ: Rapid upregulation of CTGF in cardiac myocytes by hypertrophic stimuli: implication for cardiac fibrosis and hypertrophy.J. Mol. Cell. Cardiol.37(2) , 477–481 (2004).
  • Takahashi N , CalderoneA, IzzoNJ Jr, Maki TM, Marsh JD, Colucci WS: Hypertrophic stimuli induce transforming growth factor-β 1 expression in rat ventricular myocytes. J. Clin. Invest.94(4) , 1470–1476 (1994).
  • Booth AJ , Csencsits-SmithK, WoodSC, LuG, LipsonKE, BishopDK: Connective tissue growth factor promotes fibrosis downstream of TGF-β and IL-6 in chronic cardiac allograft rejection.Am. J. Transplant.10(2) , 220–230 (2010).
  • Csencsits K , WoodSC, LuGet al.: Transforming growth factor β-induced connective tissue growth factor and chronic allograft rejection.Am. J. Transplant.6(5 Pt 1) , 959–966 (2006).
  • Raichlin E , VillarragaHR, ChandrasekaranKet al.: Cardiac allograft remodeling after heart transplantation is associated with increased graft vasculopathy and mortality.Am. J. Transplant.9(1) , 132–139 (2009).
  • Libby P , PoberJS: Chronic rejection.Immunity14(4) , 387–397 (2001).
  • Izutani H , MiyagawaS, ShirakuraRet al.: Evidence that graft coronary arteriosclerosis begins in the early phase after transplantation and progresses without chronic immunoreaction. Histopathological analysis using a retransplantation model.Transplantation60(10) , 1073–1079 (1995).
  • Jain S , FurnessPN, NicholsonML: The role of transforming growth factor β in chronic renal allograft nephropathy.Transplantation69(9) , 1759–1766 (2000).
  • Li MO , WanYY, SanjabiS, RobertsonAK, FlavellRA: Transforming growth factor-β regulation of immune responses.Annu. Rev. Immunol.24 , 99–146 (2006).
  • Border WA , NobleNA: Transforming growth factor b in tissue fibrosis.N. Engl. J. Med.331(19) , 1286–1292 (1994).
  • Cucoranu I , ClempusR, DikalovaAet al.: NAD(P)H oxidase 4 mediates transforming growth factor-β1-induced differentiation of cardiac fibroblasts into myofibroblasts.Circ. Res.97(9) , 900–907 (2005).
  • Noronha IL , NiemirZ, SteinH, WaldherrR: Cytokines and growth factors in renal disease.Nephrol. Dial. Transplant.10(6) , 775–786 (1995).
  • Zhang HY , PhanSH: Inhibition of myofibroblast apoptosis by transforming growth factor β(1).Am. J. Respir. Cell. Mol. Biol.21(6) , 658–665 (1999).
  • Brattain MG , MarkowitzSD, WillsonJK: The type II transforming growth factor-β receptor as a tumor-suppressor gene.Curr. Opin. Oncol.8(1) , 49–53 (1996).
  • Massague J , BlainSW, LoRS: TGF-β signaling in growth control, cancer, and heritable disorders.Cell103(2) , 295–309 (2000).
  • Faust SM , LuG, MariniBLet al.: Role of T cell TGF-β signaling and IL-17 in allograft acceptance and fibrosis associated with chronic rejection.J. Immunol.183(11) , 7297–7306 (2009).
  • Wood KJ , SakaguchiS: Regulatory T cells in transplantation tolerance.Nat. Rev. Immunol.3(3) , 199–210 (2003).
  • Yong Z , ChangL, MeiYX, YiL: Role and mechanisms of CD4+CD25+ regulatory T cells in the induction and maintenance of transplantation tolerance.Transpl. Immunol.17(2) , 120–129 (2007).
  • Walsh PT , TaylorDK, TurkaLA: Tregs and transplantation tolerance.J. Clin. Invest.114(10) , 1398–1403 (2004).
  • Yamaguchi Y , MannDM, RuoslahtiE: Negative regulation of transforming growth factor-β by the proteoglycan decorin.Nature346(6281) , 281–284 (1990).
  • Border WA , NobleNA, YamamotoTet al.: Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease.Nature360(6402) , 361–364 (1992).
  • Zhang Z , GarronTM, LiXJet al.: Recombinant human decorin inhibits TGF-β1-induced contraction of collagen lattice by hypertrophic scar fibroblasts.Burns35(4) , 527–537 (2009).
  • Pedagogos E , HewitsonTD, WalkerRG, NicholisKM, BeckerGJ: Myofibroblast involvement in chronic transplant rejection.Transplantation64(8) , 1192–1197 (1997).
  • Isaka Y , BreesDK, IkegayaKet al.: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney.Nat. Med.2(4) , 418–423 (1996).
  • Kolb M , MargettsPJ, SimePJ, GauldieJ: Proteoglycans decorin and biglycan differentially modulate TGF-β-mediated fibrotic responses in the lung.Am. J. Physiol. Lung Cell. Mol. Physiol.280(6) , L1327–1334 (2001).
  • Faust SM , LuG, WoodSC, BishopDK: TGF-β neutralization within cardiac allografts by decorin gene transfer attenuates chronic rejection.J. Immunol.183(11) , 7307–7313 (2009).
  • Leask A , AbrahamDJ: The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology.Biochem. Cell. Biol.81(6) , 355–363 (2003).
  • Chen MM , LamA, AbrahamJA, SchreinerGF, JolyAH: CTGF expression is induced by TGF-β in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis.J. Mol. Cell. Cardiol.32(10) , 1805–1819 (2000).
  • Daniels A , van Bilsen M, Goldschmeding R, van der Vusse GJ, van Nieuwenhoven FA: Connective tissue growth factor and cardiac fibrosis. Acta Physiol. (Oxf.)195(3) , 321–338 (2009).
  • Kundi R , HollenbeckST, YamanouchiDet al.: Arterial gene transfer of the TGF-β signalling protein Smad3 induces adaptive remodelling following angioplasty: a role for CTGF.Cardiovasc. Res.84(2) , 326–335 (2009).
  • Hayata N , FujioY, YamamotoYet al.: Connective tissue growth factor induces cardiac hypertrophy through Akt signaling.Biochem. Biophys. Res. Commun.370(2) , 274–278 (2008).
  • de Winter P , LeoniP, AbrahamD: Connective tissue growth factor: structure-function relationships of a mosaic, multifunctional protein.Growth Factors26(2) , 80–91 (2008).
  • Bonniaud P , MartinG, MargettsPJet al.: Connective tissue growth factor is crucial to inducing a profibrotic environment in “fibrosis-resistant” BALB/c mouse lungs.Am. J. Respir. Cell. Mol. Biol.31(5) , 510–516 (2004).
  • Cheng O , ThuillierR, SampsonEet al.: Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis.Am. J. Transplant.6(10) , 2292–2306 (2006).
  • Yuan YC , XiaZK, MuJJ, ZhangQC, YinBL: Increased connective tissue growth factor expression in a rat model of chronic heart allograft rejection.J. Formos. Med. Assoc.108(3) , 240–246 (2009).
  • Csencsits K , WoodSC, LuG, BishopDK: Transforming growth factor-β1 gene transfer is associated with the development of regulatory cells.Am. J. Transplant.5(10) , 2378–2384 (2005).
  • Guo X , WangXF: Signaling cross-talk between TGF-β/BMP and other pathways.Cell Res.19(1) , 71–88 (2009).
  • Bettelli E , CarrierY, GaoWet al.: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.Nature441(7090) , 235–238 (2006).
  • Chen RH , ChangMC, SuYH, TsaiYT, KuoML: Interleukin-6 inhibits transforming growth factor-β-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways.J. Biol. Chem.274(33) , 23013–23019 (1999).
  • Zhang XL , TopleyN, ItoT, PhillipsA: Interleukin-6 regulation of transforming growth factor (TGF)-β receptor compartmentalization and turnover enhances TGF-β1 signaling.J. Biol. Chem.280(13) , 12239–12245 (2005).
  • Coles B , FieldingCA, Rose-JohnS, SchellerJ, JonesSA, O‘DonnellVB: Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo.Am. J. Pathol.171(1) , 315–325 (2007).
  • Jones SA : Directing transition from innate to acquired immunity: defining a role for IL-6.J. Immunol.175(6) , 3463–3468 (2005).
  • Naugler WE , KarinM: The wolf in sheep‘s clothing: the role of interleukin-6 in immunity, inflammation and cancer.Trends Mol. Med.14(3) , 109–119 (2008).
  • Van Snick J : Interleukin-6: an overview.Annu. Rev. Immunol.8 , 253–278 (1990).
  • Takatsuki F , OkanoA, SuzukiCet al.: Human recombinant IL-6/B cell stimulatory factor 2 augments murine antigen-specific antibody responses in vitro and in vivo.J. Immunol.141(9) , 3072–3077 (1988).
  • Hurst SM , WilkinsonTS, McLoughlinRMet al.: IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation.Immunity14(6) , 705–714 (2001).
  • Lin ZQ , KondoT, IshidaY, TakayasuT, MukaidaN: Essential involvement of IL-6 in the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient mice.J. Leukoc. Biol.73(6) , 713–721 (2003).
  • Youker K , SmithCW, AndersonDCet al.: Neutrophil adherence to isolated adult cardiac myocytes. Induction by cardiac lymph collected during ischemia and reperfusion.J. Clin. Invest.89(2) , 602–609 (1992).
  • Sporri B , MullerKM, WiesmannU, BickelM: Soluble IL-6 receptor induces calcium flux and selectively modulates chemokine expression in human dermal fibroblasts.Int. Immunol.11(7) , 1053–1058 (1999).
  • Weissenbach M , ClahsenT, WeberCet al.: Interleukin-6 is a direct mediator of T cell migration.Eur. J. Immunol.34(10) , 2895–2906 (2004).
  • Fielding CA , McLoughlinRM, McLeodLet al.: IL-6 regulates neutrophil trafficking during acute inflammation via STAT3.J. Immunol.181(3) , 2189–2195 (2008).
  • McLoughlin RM , JenkinsBJ, GrailDet al.: IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation.Proc. Natl Acad. Sci. USA102(27) , 9589–9594 (2005).
  • Teague TK , MarrackP, KapplerJW, VellaAT: IL-6 rescues resting mouse T cells from apoptosis.J. Immunol.158(12) , 5791–5796 (1997).
  • Yang XO , NurievaR, MartinezGJet al.: Molecular antagonism and plasticity of regulatory and inflammatory T cell programs.Immunity29(1) , 44–56 (2008).
  • Wan S , XiaC, MorelL: IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions.J. Immunol.178(1) , 271–279 (2007).
  • Pasare C , MedzhitovR: Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells.Science299(5609) , 1033–1036 (2003).
  • Zhao XM , FristWH, YeohTK, MillerGG: Expression of cytokine genes in human cardiac allografts: correlation of IL-6 and transforming growth factor-β (TGF-β) with histological rejection.Clin. Exp. Immunol.93(3) , 448–451 (1993).
  • Liang Y , ChristopherK, FinnPW, ColsonYL, PerkinsDL: Graft produced interleukin-6 functions as a danger signal and promotes rejection after transplantation.Transplantation84(6) , 771–777 (2007).
  • Chen L , AhmedE, WangTet al.: TLR signals promote IL-6/IL-17-dependent transplant rejection.J. Immunol.182(10) , 6217–6225 (2009).
  • Erten Y , TulmacM, DericiUet al.: An association between inflammatory state and left ventricular hypertrophy in hemodialysis patients.Ren. Fail.27(5) , 581–589 (2005).
  • Fredj S , BescondJ, LouaultC, PotreauD: Interactions between cardiac cells enhance cardiomyocyte hypertrophy and increase fibroblast proliferation.J. Cell. Physiol.202(3) , 891–899 (2005).
  • Kurdi M , RandonJ, CeruttiC, BriccaG: Increased expression of IL-6 and LIF in the hypertrophied left ventricle of TGR(mRen2)27 and SHR rats.Mol. Cell. Biochem.269(1–2) , 95–101 (2005).
  • Sano M , FukudaK, KodamaHet al.: Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes.J. Biol. Chem.275(38) , 29717–29723 (2000).
  • Briest W , RasslerB, DetenAet al.: Norepinephrine-induced interleukin-6 increase in rat hearts: differential signal transduction in myocytes and non-myocytes.Pflugers Arch.446(4) , 437–446 (2003).
  • Birks EJ , BurtonPB, OwenVet al.: Elevated tumor necrosis factor-α and interleukin-6 in myocardium and serum of malfunctioning donor hearts.Circulation102(19 Suppl. 3) , III352–III358 (2000).
  • Hirota H , IzumiM, HamaguchiTet al.: Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure.Heart Vessels19(5) , 237–241 (2004).
  • Torre-Amione G , KapadiaS, BenedictC, OralH, YoungJB, MannDL: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD).J. Am. Coll. Cardiol.27(5) , 1201–1206 (1996).
  • Tsutamoto T , HisanagaT, WadaAet al.: Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure.J. Am. Coll. Cardiol.31(2) , 391–398 (1998).
  • Vasan RS , SullivanLM, RoubenoffRet al.: Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study.Circulation107(11) , 1486–1491 (2003).
  • Sarkar S , VellaichamyE, YoungD, SenS: Influence of cytokines and growth factors in ANG II-mediated collagen upregulation by fibroblasts in rats: role of myocytes.Am. J. Physiol. Heart Circ. Physiol.287(1) , H107–117 (2004).
  • Fredj S , BescondJ, LouaultC, DelwailA, LecronJC, PotreauD: Role of interleukin-6 in cardiomyocyte/cardiac fibroblast interactions during myocyte hypertrophy and fibroblast proliferation.J. Cell. Physiol.204(2) , 428–436 (2005).
  • Liu X , DasAM, SeidemanJet al.: The CC chemokine ligand 2 (CCL2) mediates fibroblast survival through IL-6.Am. J. Respir. Cell. Mol. Biol.37(1) , 121–128 (2007).
  • Burlingham WJ , LoveRB, Jankowska-GanEet al.: IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants.J. Clin. Invest.117(11) , 3498–3506 (2007).
  • Fukami N , RamachandranS, SainiDet al.: Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection.J. Immunol.182(1) , 309–318 (2009).
  • Simonian PL , RoarkCL, WehrmannFet al.: Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis.J. Immunol.182(1) , 657–665 (2009).
  • Yuan X , Paez-CortezJ, Schmitt-KnosallaIet al.: A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy.J. Exp. Med.205(13) , 3133–3144 (2008).
  • Venkatachalam K , MummidiS, CortezDM, PrabhuSD, ValenteAJ, ChandrasekarB: Resveratrol inhibits high glucose-induced PI3K/Akt/ERK-dependent interleukin-17 expression in primary mouse cardiac fibroblasts.Am. J. Physiol. Heart Circ. Physiol.294(5) , H2078–H2087 (2008).
  • Feng W , LiW, LiuW, WangF, LiY, YanW: IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure.Exp. Mol. Pathol.87(3) , 212–218 (2009).
  • Cortez DM , FeldmanMD, MummidiSet al.: IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1/2-dependent C/EBP-β, NF-κB, and AP-1 activation.Am. J. Physiol. Heart Circ. Physiol.293(6) , H3356–H3365 (2007).
  • Chabaud M , FossiezF, TaupinJL, MiossecP: Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines.J. Immunol.161(1) , 409–414 (1998).
  • Wang L , YiT, KortylewskiM, PardollDM, ZengD, YuH: IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway.J. Exp. Med.206(7) , 1457–1464 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.